Ortiz MJ

Language: Spanish
References: 3
Page: 85-86
PDF size: 89.55 Kb.

REFERENCES

1. Hauser SL, Cross AH, Winthrop K, Wiendl H, Nicholas J, Meuth SG, et al. Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years. Mult Scler. 2022; 28 (10): 1576-1590.

2. Compendio Nacional para Insumos para la Salud. México: COFEPRIS; 2020.

3. Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020; 383 (6): 546-557.